Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Endocr Relat Cancer. 2019 Oct;26(10):765–778. doi: 10.1530/ERC-19-0262

Figure 6.

Figure 6.

HITOPK032 inhibits tumorigenic growth in ACC. A. HITOPK032 treatment in athymic nude mice bearing passage 14 CU-ACC1 PDXs shows significant decrease in tumor rate by day 14 and day 17 (**p<0.01). B. A representative image of tumors harvested at the end of the study. Treated group has smaller tumor size compared to control. C. Graph showing growth rates of individual tumors following HITOPK032 treatment. D. Average net weight of mice in treated and the control group shows no significant change in body weight. E. IHC analysis of pH3 in tissue sections of control and treated tumors. There is 1.9 fold decrease in histone 3 phosphorylation in treated group relative to control ( **p<0.01). F. Immunoblot of representative tumor lysates from 5 control and 6 treated tumors collected from individual mice showing difference in cleaved PARP, cleaved caspase 3, pAkt and pJNK expression between control and treated group (*p<0.05, **p<0.01)